Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind study of subcutaneous RO7790121 in moderate to severe active Crohn's disease
NL-OMON58808Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing RO7790121 with Placebo (2 arms). Primary endpoint: Incidence of TEAEs, SAEs, and AEs leading to discontinuation. Started Sep 2023; status: completed.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON58808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58808.